(Q41937791)

English

Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial

scientific article published on August 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 October 2017

Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 October 2017

hydroxychloroquine

1 reference

based on heuristic

inferred from title

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

L Ljung

15

0 references

author name string

R F van Vollenhoven

1

1 reference

Europe PubMed Central

PubMed publication ID

14 October 2017

S Ernestam

2

1 reference

Europe PubMed Central

PubMed publication ID

14 October 2017

P Geborek

3

1 reference

Europe PubMed Central

PubMed publication ID

14 October 2017

I F Petersson

4

1 reference

Europe PubMed Central

PubMed publication ID

14 October 2017

L Cöster

5

1 reference

Europe PubMed Central

PubMed publication ID

14 October 2017

E Waltbrand

6

1 reference

Europe PubMed Central

PubMed publication ID

14 October 2017

A Zickert

7

1 reference

Europe PubMed Central

PubMed publication ID

14 October 2017

J Theander

8

1 reference

Europe PubMed Central

PubMed publication ID

14 October 2017

A Thörner

9

1 reference

Europe PubMed Central

PubMed publication ID

14 October 2017

H Hellström

10

1 reference

Europe PubMed Central

PubMed publication ID

14 October 2017

A Teleman

11

1 reference

Europe PubMed Central

PubMed publication ID

14 October 2017

C Dackhammar

12

1 reference

Europe PubMed Central

PubMed publication ID

14 October 2017

F Akre

13

1 reference

Europe PubMed Central

PubMed publication ID

14 October 2017

K Forslind

14

1 reference

Europe PubMed Central

PubMed publication ID

14 October 2017

R Oding

16

1 reference

Europe PubMed Central

PubMed publication ID

14 October 2017

A Chatzidionysiou

17

1 reference

Europe PubMed Central

PubMed publication ID

14 October 2017

M Wörnert

18

1 reference

Europe PubMed Central

PubMed publication ID

14 October 2017

J Bratt

19

1 reference

Europe PubMed Central

PubMed publication ID

14 October 2017

language of work or name

0 references

publication date

1 August 2009

1 reference

Europe PubMed Central

PubMed publication ID

14 October 2017

1 reference

Europe PubMed Central

PubMed publication ID

14 October 2017

374

1 reference

Europe PubMed Central

PubMed publication ID

14 October 2017

9688

1 reference

Europe PubMed Central

PubMed publication ID

14 October 2017

459-466

1 reference

Europe PubMed Central

PubMed publication ID

14 October 2017

The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960944-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960944-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960944-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960944-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960944-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960944-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960944-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960944-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960944-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination Therapy with Cyclosporine and Methotrexate in Severe Rheumatoid Arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960944-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960944-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960944-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose escalation of infliximab in clinical practice: improvements seen may be explained by a regression-like effect

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960944-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its efficacy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960944-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumati

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960944-2

7 January 2021

based on heuristic

inferred from DOI database lookup

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960944-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960944-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical identification and treatment of a rapidly progressing disease state in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960944-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960944-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960944-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twe

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960944-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960944-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(09)60944-2

1 reference

Europe PubMed Central

PubMed publication ID

14 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41937791&oldid=1930079676"